Gujiansan Ameliorates Avascular Necrosis of the Femoral Head by Regulating Autophagy via the HIF-1α/BNIP3 Pathway

Table 2

Concentrations of OC, BAP, TRACP-5b, NTX-1, and CTX-1 in each group on the 2nd, 4th, and 8th weeks (n = 6).

Groups	Week	OC (pg/ml)	BAP (ng/ml)	TRACP-5b (ng/ml)	NTX-1 (ng/ml)	CTX-1 (pg/ml)
Normal	2	136.05 ± 3.81	12.50 ± 0.40	4.58 ± 0.21	6.64 ± 1.20	415.40 ± 24.42
	4	133.59 ± 5.67	11.64 ± 0.66	4.90 ± 0.36	7.60 ± 1.22	404.77 ± 25.58
	8	131.55 ± 4.77	12.66 ± 0.83	4.99 ± 0.46	7.80 ± 1.15	428.93 ± 23.21
Model	2	8.78 ± 2.13	0.70 ± 0.41	0.22 ± 0.065	2.98 ± 0.17	152.78 ± 7.81
	4	7.31 ± 2.48	0.76 ± 0.28	0.18 ± 0.041	2.81 ± 0.14	157.25 ± 11.04
	8	10.35 ± 3.31	0.86 ± 0.51	0.20 ± 0.066	2.95 ± 0.19	154.90 ± 10.63
L-Gujiansan	2	22.35 ± 5.46^#	1.63 ± 0.15^#	0.42 ± 0.10^#	3.30 ± 0.073^#	171.32 ± 4.31^#
	4	23.50 ± 3.46^#	2.19 ± 0.59^#▼	0.72 ± 0.11^#▼	3.46 ± 0.072^#	182.30 ± 13.60^#
	8	26.90 ± 6.84^#▼	2.35 ± 0.31^#▼	0.84 ± 0.13^#▼	3.51 ± 0.15^#▼	192.53 ± 4.28^#▼
M-Gujiansan	2	40.58 ± 3.97^#&	3.03 ± 0.30^#	0.83 ± 0.12^#&	3.50 ± 0.11^#&	201.53 ± 12.10^#&
	4	40.77 ± 7.07^#&	3.58 ± 0.57^#&	1.06 ± 0.26^#&▼	3.83 ± 0.33^#&	220.85 ± 11.78^#&▼
	8	48.06 ± 2.36^#&▼	3.71 ± 0.27^#&▼	1.10 ± 0.19^#&▼	3.83 ± 0.12^#&▼	225.88 ± 12.96^#&▼
H-Gujiansan	2	54.33 ± 4.99^#&	4.16 ± 0.26^#&	1.51 ± 0.23^#&	4.24 ± 0.24^#&	230.83 ± 8.37^#&
	4	54.22 ± 3.47^#&	5.07 ± 0.27^#&▼	1.59 ± 0.18^#&	4.36 ± 0.47^#&	241.90 ± 7.60^#&▼
	8	58.55 ± 4.96^#&▼	5.11 ± 0.34^#&▼	1.71 ± 0.24^#&▼	4.40 ± 0.25^#&	247.99 ± 11.14^#&▼
Pravastatin	2	64.76 ± 9.53^#	6.15 ± 0.69^#	2.18 ± 0.35^#	4.68 ± 0.063^#	261.37 ± 7.17^#
	4	70.42 ± 10.58^#	6.17 ± 0.81^#	2.21 ± 0.19^#	4.80 ± 0.19^#	267.53 ± 13.37^#
	8	72.72 ± 4.22^#▼	7.09 ± 0.49^#▼	2.70 ± 0.14^#▼	5.09 ± 0.13^#▼	282.93 ± 18.49^#▼

Data are represented as the means ± SD (n = 6). vs. the normal group. ^# vs. the model group. ^& vs. L-Gujiansan corresponding weeks’ group. ^▼ vs. corresponding 2 weeks’ group.